Decreased expression of hMLH1 correlates with reduced 5-fluorouracil- mediated apoptosis in colon cancer cells

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1129-1137

  Fujita, Hideyuki ^a   Kato, Jun ^a   Horii, Joichiro ^a   Harada, Keita ^a   Hiraoka, Sakiko ^a   Shiraha, Hidenori ^a   Sakaguchi, Kohsaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Apoptosis; Chemosensitivity; Colorectal cancer; hMLH1

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; MESSENGER RNA; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; COLON TUMOR; DNA METHYLATION; DNA REPAIR; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; COLONIC NEOPLASMS; DNA METHYLATION; DNA REPAIR; FLUOROURACIL; HUMANS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 38449105001     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Thibodeau SN, French AJ, Cunningham JM, et al: Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 58: 1713-1718, 1998. (Pubitemid 28215098)
2. Veigl ML, Kasturi L, Olechnowicz J, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95: 8698-8702, 1998. (Pubitemid 28350551)
3. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58: 3455-3460, 1998. (Pubitemid 28371090)
4. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808-811, 1997. (Pubitemid 27097998)
5. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998. (Pubitemid 28278073)
6. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260: 816-819, 1993. (Pubitemid 23167612)
7. Wheeler JM, Bodmer WF, Mortensen NJ: DNA mismatch repair genes and colorectal cancer. Gut 47: 148-153, 2000. (Pubitemid 30430425)
8. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
9. Souza RF, Appel R, Yin J, et al: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 14: 255-257, 1996.
10. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969, 1997. (Pubitemid 27087710)
11. Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53: 5849-5852, 1993. (Pubitemid 24006146)
12. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77, 2000. (Pubitemid 30036597)
13. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91: 1295-1303, 1999. (Pubitemid 29387571)
14. Lukish JR, Muro K, DeNobile J, et al: Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227: 51-56, 1998. (Pubitemid 28071337)
15. Bubb VJ, Curtis LJ, Cunningham C, et al: Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12: 2641-2649, 1996. (Pubitemid 26237793)
16. Wright CM, Dent OF, Barker M, et al: Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87: 1197-1202, 2000.
17. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257, 2003. (Pubitemid 36859476)
18. Carethers JM, Smith EJ, Behling CA, et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126: 394-401, 2004. (Pubitemid 38182296)
19. Jover R, Zapater P, Castells A, et al: Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55: 848-855, 2006. (Pubitemid 43764557)
20. Koi M, Umar A, Chauhan DP, et al: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312, 1994.
21. Van der Weyden L, Tachibana KK, Gonzalez MA, et al: The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 25: 8356-8367, 2005. (Pubitemid 41263023)
22. Zhuang Z, Emmert-Buck MR, Roth MJ, et al: Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 27: 152-156, 1996. (Pubitemid 26049468)
23. Giles RH, Lolkema MP, Snijckers CM, et al: Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25: 3065-3070, 2006. (Pubitemid 43780471)
24. Biswas S, Chytil A, Washington K, et al: Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 64: 4687-4692, 2004. (Pubitemid 38924506)
25. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66-73, 2003. (Pubitemid 36750389)
26. Raschle M, Marra G, Nystrom-Lahti M, Schar P, Jiricny J: Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J Biol Chem 274: 32368-32375, 1999.
27. Meyers M, Hwang A, Wagner MW, et al: A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22: 7376-7388, 2003.
28. Carethers JM, Chauhan DP, Fink D, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131, 1999. (Pubitemid 29297628)
29. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA: Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61: 5193-5201, 2001. (Pubitemid 32681553)
30. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA: DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280: 5516-5526, 2005. (Pubitemid 40280029)
31. Zhang H, Richards B, Wilson T, et al: Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 59: 3021-3027, 1999. (Pubitemid 29315993)
32. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
33. Bunz F, Hwang PM, Torrance C, et al: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269, 1999.
34. Longley DB, Boyer J, Allen WL, et al: The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62: 2644-2649, 2002. (Pubitemid 34462747)
35. Boyer J, McLean EG, Aroori S, et al: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10: 2158-2167, 2004. (Pubitemid 38375578)
36. Liang JT, Huang KC, Cheng YM, et al: P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97: 451-457, 2002.
37. Elsaleh H, Powell B, McCaul K, et al: P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7: 1343-1349, 2001. (Pubitemid 32708690)
38. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58: 1149-1158, 1998. (Pubitemid 28183202)
39. Umar A, Buermeyer AB, Simon JA, et al: Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 87: 65-73, 1996. (Pubitemid 26337391)